Lipocine Inc.: announces Health Canada approval of TLANDO®

What happened

• The filing says Lipocine Inc announced Health Canada approval of TLANDO® for testosterone replacement therapy. The company filed the Form 8-K on Oct 7, 2026.
• The filing states, "A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein."

Key details

• Item reported: Item 8.01 (Other events).
• Filing date: Oct 7, 2026.
• The press release was furnished as Exhibit 99.1 and is incorporated by reference.

Why it may matter

• The filing reports Item 8.01, which covers other events the company chooses to disclose, and in this case furnishes a press release announcing Health Canada approval of TLANDO®.
• A filing does not show why the insider traded or why the company acted.